A Study to Evaluate Opevesostat (MK-5684) in Male Participants With Moderate Hepatic Impairment (MK-5684-009)
An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of MK-5684 in Male Participants With Moderate Hepatic Impairment
Sponsor: Merck Sharp & Dohme LLC
Listed as NCT06860243, this PHASE1 trial focuses on Healthy Participants and Hepatic Impairment and remains completed. Sponsored by Merck Sharp & Dohme LLC, it has been updated 9 times since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Feb 2026 — Present [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Jan 2026 — Feb 2026 [monthly]
Recruiting PHASE1
-
Dec 2025 — Jan 2026 [monthly]
Recruiting PHASE1
-
Oct 2025 — Dec 2025 [monthly]
Recruiting PHASE1
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE1
▶ Show 4 earlier versions
-
Jul 2025 — Sep 2025 [monthly]
Recruiting PHASE1
-
Jun 2025 — Jul 2025 [monthly]
Recruiting PHASE1
-
May 2025 — Jun 2025 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Apr 2025 — May 2025 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Merck Sharp & Dohme LLC
For direct contact, visit the study record on ClinicalTrials.gov .